Potential of the cannabinoid CB2 receptor as a pharmacological target against inflammation in Parkinson's disease

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 64, Issue , 2016, Pages 200-208

  Gómez Gálvez, Yolanda ^a,b,c   Palomo Garo, Cristina ^a,b,c   Fernández Ruiz, Javier ^a,b,c   García, Concepción ^a,b,c  

^a UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^b CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED SOBRE ENFERMEDADES NEURODEGENERATIVAS CIBERNED   (Spain)

^c INSTITUTO RAMÓN Y CAJAL DE INVESTIGACIÓN SANITARIA IRYCIS   (Spain)

Author keywords

Cannabinoids; CB2 receptors; Glial activation; Inflammation; LPS; Parkinson's disease

Indexed keywords

4 [4 (1,1 DIMETHYLHEPTYL) 2,6 DIMETHOXYPHENYL] 6,6 DIMETHYLBICYCLO[3.1.1]HEPT 2 EN 2 YLMETHANOL; CANNABINOID 2 RECEPTOR; CD68 ANTIGEN; INDUCIBLE NITRIC OXIDE SYNTHASE; LIPOPOLYSACCHARIDE; TYROSINE 3 MONOOXYGENASE; ANTIPARKINSON AGENT; CANNABINOID; CANNABINOID RECEPTOR AFFECTING AGENT; CNR2 PROTEIN, HUMAN; CNR2 PROTEIN, MOUSE;

ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL INFILTRATION; CONTROLLED STUDY; CORPUS STRIATUM; DRUG RECEPTOR BINDING; DRUG TARGETING; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; INFLAMMATION; MACROPHAGE; MALE; MICROGLIA; MIDDLE AGED; MOUSE; NONHUMAN; PARKINSON DISEASE; SUBSTANTIA NIGRA; UPREGULATION; VERY ELDERLY; ANIMAL; C57BL MOUSE; DRUG EFFECTS; GENETICS; IMMUNOLOGY; KNOCKOUT MOUSE; METABOLISM; PARKINSONIAN DISORDERS; PATHOLOGY;

AGED; AGED, 80 AND OVER; ANIMALS; ANTIPARKINSON AGENTS; CANNABINOID RECEPTOR MODULATORS; CANNABINOIDS; CORPUS STRIATUM; FEMALE; HUMANS; LIPOPOLYSACCHARIDES; MACROPHAGES; MALE; MICE, INBRED C57BL; MICE, KNOCKOUT; MICROGLIA; MIDDLE AGED; PARKINSONIAN DISORDERS; RECEPTOR, CANNABINOID, CB2; SUBSTANTIA NIGRA;

EID: 84941169958     PISSN: 02785846     EISSN: 18784216     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2015.03.017     Document Type: Article

References (40)

1. Antunes F., Han D., Rettori D., Cadenas E. Mitochondrial damage by nitric oxide is potentiated by dopamine in PC12 cells. Biochim Biophys Acta 2002, 1556:233-238.
2. Arimoto T., Bing G. Up-regulation of inducible nitric oxide synthase in the substantia nigra by lipopolysaccharide causes microglial activation and neurodegeneration. Neurobiol Dis 2003, 12:35-45.
3. Benito C., Nuñez E., Tolon R.M., Carrier E.J., Rábano A., Hillard C.J., et al. Cannabinoid CB2 receptors and fatty acid amide hydrolase are selectively overexpressed in neuritic plaque-associated glia in Alzheimer's disease brains. J Neurosci 2003, 23:11136-11141.
4. Buckley N.E. The peripheral cannabinoid receptor knockout mice: an update. Br J Pharmacol 2008, 153:309-318.
5. Buckley N.E., McCoy K.L., Mezey E., Bonner T., Zimmer A., Felder C.C., et al. Immunomodulation by cannabinoids is absent in mice deficient for the cannabinoid CB2 receptor. Eur J Pharmacol 2000, 396:141-149.
6. Carrier E.J., Kearn C.S., Barkmeier A.J., Breese N.M., Yang W., Nithipatikom K., et al. Cultured rat microglial cells synthesize the endocannabinoid 2-arachidonylglycerol, which increases proliferation via a CB2 receptor-dependent mechanism. Mol Pharmacol 2004, 65:999-1007.
7. Chen H., Jacobs E., Schwarzschild M.A., McCullough M.L., Calle E.E., Thun M.J., et al. Nonsteroidal antiinflammatory drug use and the risk for Parkinson's disease. Ann Neurol 2005, 58:963-967.
8. Chiurchiù V., Leuti A., Maccarrone M. Cannabinoid signaling and neuroinflammatory diseases: a melting pot for the regulation of brain immune responses. J Neuroimmune Pharmacol 2015, (in press).
9. Choi D.Y., Liu M., Hunter R.L., Cass W.A., Pandya J.D., Sullivan P.G., et al. Striatal neuroinflammation promotes Parkinsonism in rats. PLoS One 2009, 4:e5482.
10. Chung Y.C., Bok E., Huh S.H., Park J.Y., Yoon S.H., Kim S.R., et al. Cannabinoid receptor type 1 protects nigrostriatal dopaminergic neurons against MPTP neurotoxicity by inhibiting microglial activation. J Immunol 2011, 187:6508-6517.
11. de Lago E., Moreno-Martet M., Cabranes A., Ramos J.A., Fernández-Ruiz J. Cannabinoids ameliorate disease progression in a model of multiple sclerosis in mice, acting preferentially through CB1 receptor-mediated anti-inflammatory effects. Neuropharmacology 2012, 62:2299-2308.
12. 1 receptor activation inhibits neuronal and astrocytic intermediary metabolism in the rat hippocampus. Neurochem Int 2012, 60:1-8.
13. Fernández-Ruiz J., Romero J., Velasco G., Tolón R.M., Ramos J.A., Guzmán M. Cannabinoid CB2 receptor: a new target for controlling neural cell survival?. Trends Pharmacol Sci 2007, 28:39-45.
14. Fernández-Ruiz J., García C., Sagredo O., Gómez-Ruiz M., de Lago E. The endocannabinoid system as a target for the treatment of neuronal damage. Expert Opin Ther Targets 2010, 14:387-404.
15. Fidaleo M., Fanelli F., Ceru M.P., Moreno S. Neuroprotective properties of peroxisome proliferator-activated receptor-α (PPARα) and its lipid ligands. Curr Med Chem 2014, 21:2803-2821.
16. 9-THCV in animal models of Parkinson's disease. Br J Pharmacol 2011, 163:1495-1506.
17. García M.C., Cinquina V., Palomo-Garo C., Rábano A., Fernández-Ruiz J. Identification of CB2 receptors in human nigral neurons that degenerate in Parkinson's disease. Neurosci Lett 2015, 587:1-4.
18. García-Arencibia M., González S., de Lago E., Ramos J.A., Mechoulam R., Fernández-Ruiz J. Evaluation of the neuroprotective effect of cannabinoids in a rat model of Parkinson's disease: importance of antioxidant and cannabinoid receptor-independent properties. Brain Res 2007, 1134:162-170.
19. Herrera A.J., Castaño A., Venero J.L., Cano J., Machado A. The single intranigral injection of LPS as a new model for studying the selective effects of inflammatory reactions on dopaminergic system. Neurobiol Dis 2000, 7:429-447.
20. Hisano S., Haga H., Miyamoto K., Takeda E., Fukui Y. The basic amino acid transporter (rBAT)-like immunoreactivity in paraventricular and supraoptic magnocellular neurons of the rat hypothalamus. Brain Res 1996, 710:299-302.
21. Hunter R.L., Cheng B., Choi D.Y., Liu M., Liu S., Cass W.A., et al. Intrastriatal lipopolysaccharide injection induces parkinsonism in C57/B6 mice. J Neurosci Res 2009, 87:1913-1921.
22. Jung B.D., Shin E.J., Nguyen X.K., Jin C.H., Bach J.H., Park S.J., et al. Potentiation of methamphetamine neurotoxicity by intrastriatal lipopolysaccharide administration. Neurochem Int 2010, 56:229-244.
23. Knott C., Stern G., Wilkin G.P. Inflammatory regulators in Parkinson's disease: iNOS, lipocortin-1, and cyclooxygenases-1 and -2. Mol Cell Neurosci 2000, 16:724-739.
24. Lanciego J.L., Barroso-Chinea P., Rico A.J., Conte-Perales L., Callén L., Roda E., et al. Expression of the mRNA coding the cannabinoid receptor 2 in the pallidal complex of Macaca fascicularis. J Psychopharmacol 2011, 25:97-104.
25. Liberatore G.T., Jackson-Lewis V., Vukosavic S., Mandir A.S., Vila M., McAuliffe W.G., et al. Inducible nitric oxide synthase stimulates dopaminergic neurodegeneration in the MPTP model of Parkinson disease. Nat Med 1999, 5:1403-1409.
26. Molina-Holgado F., Pinteaux E., Moore J.D., Molina-Holgado E., Guaza C., Gibson R.M., et al. Endogenous interleukin-1 receptor antagonist mediates anti-inflammatory and neuroprotective actions of cannabinoids in neurons and glia. J Neurosci 2003, 23:6470-6474.
27. Oh Y.T., Lee J.Y., Lee J., Lee J.H., Kim J.E., Ha J., et al. Oleamide suppresses lipopolysaccharide-induced expression of iNOS and COX-2 through inhibition of NFκB activation in BV2 murine microglial cells. Neurosci Lett 2010, 474:148-153.
28. Ouchi Y., Yoshikawa E., Sekine Y., Futatsubashi M., Kanno T., Ogusu T., et al. Microglial activation and dopamine terminal loss in early Parkinson's disease. Ann Neurol 2005, 57:168-175.
29. Palazuelos J., Aguado T., Pazos M.R., Julien B., Carrasco C., Resel E., et al. Microglial CB2 cannabinoid receptors are neuroprotective in Huntington's disease excitotoxicity. Brain 2009, 132:3152-3164.
30. Palkovits M., Brownstein J. Maps and guide to microdissection of the rat brain 1988, Elsevier.
31. Price D.A., Martinez A.A., Seillier A., Koek W., Acosta Y., Fernández E., et al. WIN55,212-2, a cannabinoid receptor agonist, protects against nigrostriatal cell loss in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease. Eur J Neurosci 2009, 29:2177-2186.
32. Rodríguez-Cueto C., Benito C., Fernández-Ruiz J., Romero J., Hernández-Gálvez M.L., Gómez-Ruiz M. Changes in CB1 and CB2 receptors in the post-mortem cerebellum of humans affected by spinocerebellar ataxias. Br J Pharmacol 2014, 171:1472-1489.
33. Sagredo O., González S., Aroyo I., Pazos M.R., Benito C., Lastres-Becker I., et al. Cannabinoid CB2 receptor agonists protect the striatum against malonate toxicity: relevance for Huntington's disease. Glia 2009, 57:1154-1167.
34. Sheng W.S., Hu S., Ni H.T., Rock R.B., Peterson P.K. WIN55,212-2 inhibits production of CX3CL1 by human astrocytes: involvement of p38 MAP kinase. J Neuroimmune Pharmacol 2009, 4:244-248.
35. Smith S.R., Terminelli C., Denhardt G. Effects of cannabinoid receptor agonist and antagonist ligands on production of inflammatory cytokines and anti-inflammatory interleukin-10 in endotoxemic mice. J Pharmacol Exp Ther 2000, 293:136-150.
36. Stella N. Cannabinoid and cannabinoid-like receptors in microglia, astrocytes, and astrocytomas. Glia 2010, 58:1017-1030.
37. 2 cannabinoid receptors results in neuroprotection against behavioral and neurochemical alterations induced by intracaudate administration of 6-hydroxydopamine. Neurobiol Aging 2012, 33. [421 e1-e16].
38. Walter L., Franklin A., Witting A., Wade C., Xie Y., Kunos G., et al. Non-psychotropic cannabinoid receptors regulate microglial cell migration. J Neurosci 2003, 23:1398-1405.
39. Yiangou Y., Facer P., Durrenberger P., Chessell I.P., Naylor A., Bountra C., et al. COX-2, CB2 and P2X7-immunoreactivities are increased in activated microglial cells/macrophages of multiple sclerosis and amyotrophic lateral sclerosis spinal cord. BMC Neurol 2006, 6:12.
40. Zhang F., Zhou H., Wilson B.C., Shi J.S., Hong J.S., Gao H.M. Fluoxetine protects neurons against microglial activation-mediated neurotoxicity. Parkinsonism Relat Disord 2012, 18:S213-S217.